Objective: Medical students experience high psychological demands that predispose them to stress, anxiety, and depression. This study aimed to determine the prevalence of stress, anxiety, and depression in 4th-year MBBS students and measure the efficacy of a short-term mindfulness-based life coaching (MBLC) intervention. Methods: This study consisted of a cross-sectional screening followed by a...
Ketamine, a dissociative anesthetic introduced in the 1960s, has re-emerged as a versatile therapeutic agent extending beyond its traditional perioperative role. Its rapid antidepressant action in treatment-resistant depression and efficacy in acute and chronic pain syndromes have driven what is termed the “ketamine renaissance.” Unlike conventional monoaminergic antidepressants, ketamine...
Treatment resistance (TR) in major depressive disorder (MDD) affects a substantial minority of patients and is hard to recognize early, delaying intensified care. The Esketamine multi-omic biomarker evaluation in MDD (EMBER-MDD) is a non-interventional, investigator-initiated, in-vitro study within the EU Psych-STRATA programme, analyzing biospecimens collected in the randomized INTENSIFY study...
Major depressive disorder, or MDD, is a common cause of disability around the world. Treatment-resistant depression, or TRD, is a tough challenge. Many people do not respond well to treatment, which increases the risk of relapse and suicide. Esketamine is a new treatment that comes as a nasal spray. It works quickly and targets a specific brain receptor. This review looks at research from...
NeuropsychiatrieJune 30, 2026Cielo A Estela-Fernandez, Reem Mohamed Yousif Elsheikh, Dal Bianco Beatrice et al.
Major depressive disorder (MDD) is a heterogeneous, debilitating disorder. A distinct subgroup within the MDD spectrum is identified to have treatment-resistant depression (TRD). There is an impetus to find alternative treatments for TRD to reduce disease burden and improve quality of life. Psychedelics have been used in the treatment of various psychiatric disorders since the 1950s, with...
The mass evacuation of Israeli residents from conflict zones after the events of October 7, 2023, coupled with ongoing security threats, has taken a substantial psychological toll, with many individuals exhibiting symptoms of post-traumatic stress disorder (PTSD), anxiety, and sleep problems. This pilot study examined the feasibility and preliminary within-group changes associated with...
Major depressive disorder (MDD) ranks among the foremost contributors to disability worldwide, yet its neurophysiological mechanisms remain poorly understood. Excitation-inhibition (E/I) imbalance has been implicated in MDD pathophysiology, but cortex-wide E/I ratio and its molecular substrates in MDD remain unknown. Resting-state functional magnetic resonance imaging data from 254 MDD patients...
An individualized one‐day dosing regimen of a vaporized formulation of the psychedelic mebufotenin (5‐methoxy‐ N,N ‐dimethyltryptamine; 5‐MeO‐DMT) was more effective than placebo in improving depressive symptoms in adults with treatment‐resistant depression, a Phase 2b trial has found. No serious treatment‐emergent adverse events were reported during the 7‐day study. Results were published...
To explore the associations between mindfulness, psychological distress, and health-related quality of life (HRQOL), and examine whether psychological distress mediates the association between mindfulness and HRQOL in individuals with Parkinson's disease (PD). This is a secondary analysis of baseline data from a clinical trial investigating mindfulness-based interventions in patients with...
The U.S. Food and Drug Administration (FDA) has increasingly focused on breakthrough molecular mechanisms, rapidly acting medications, and expanded therapeutic indications in the treatment of depression. During this period, psychiatric interventions targeting N-methyl-D-aspartate (NMDA) receptors and intracellular signaling pathways have gained prominence, moving beyond the traditional...